Breaking News Instant updates and real-time market news.

CLF

Cleveland-Cliffs

, TECK

Teck Resources

09:40
10/13/17
10/13
09:40
10/13/17
09:40

Unusually active option classes on open October 13th

Unusual total active option classes on open include: Cliffs Natural (CLF), Teck Resources (TECK), Transocean (RIG), Wells Fargo (WFC), US Steel (X), Citi (C), Financial Sector SPDR (XLF), Equifax (EFX), Bank of America (BAC), and AT&T (T).

CLF

Cleveland-Cliffs

TECK

Teck Resources

RIG

Transocean

WFC

Wells Fargo

X

U.S. Steel

C

Citi

XLF

Financial Select Sector

EFX

Equifax

BAC

Bank of America

T

AT&T

  • 13

    Oct

  • 13

    Oct

  • 13

    Oct

  • 20

    Oct

  • 22

    Oct

  • 24

    Oct

  • 26

    Oct

  • 26

    Oct

  • 01

    Nov

  • 01

    Nov

  • 29

    Nov

  • 29

    Nov

  • 14

    Dec

  • 15

    Jan

CLF Cleveland-Cliffs

03/27/17
JPMS
03/27/17
NO CHANGE
Target $13
JPMS
Overweight
JPMorgan ups Cliffs target to $13 on higher iron ore prices
JPMorgan analyst Michael Gambardella raised his price target for Cliffs Natural Resources to $13 from $12 citing his firm's higher iron ore price forecasts. Chinese steel demand has proven to be more resilient, Gambardella tells investors in a research note. The analyst keeps an Overweight rating on Cliffs.
07/31/17
AXIO
07/31/17
NO CHANGE
AXIO
Sell
Axiom says 'now is the time' to short U.S. Steel, maintains Sell rating
Axiom analyst Gordon Johnson II believes "now is the time" to short U.S. Steel (X) and Cliffs Natural (CLF) shares and to go underweight the U.S. steel sector, as he sees an increasing likelihood of an indefinite delay in the US Commerce Department's 232 steel tariff decision. He also thinks the contribution to China's GDP growth from commodity-intensive sectors may have peaked, he tells investors. The analyst keeps a Sell rating on U.S. Steel shares.
09/25/17
MSCO
09/25/17
NO CHANGE
MSCO
Morgan Stanley raising price targets on Metals & Mining stocks
Morgan Stanley analyst Piyush Sood is "more constructive" in his outlook for base metals and met coal stocks and raised his price targets on Alcoa (AA) to $54 from $47, Freeport-McMoRan (FCX) to $10 from $8, Teck Resources (TECK) to $20 from $17, Newmont Mining (NEM) to $33 from $31, and Warrior Met Coal (HCC) to $22 from $17. Sood added that Alcoa remains his top pick. However, Sood lowered the price target of Cleveland-Cliffs (CLF) to $7 from $8.
04/28/17
FBRC
04/28/17
UPGRADE
FBRC
Outperform
Cliffs Natural upgraded to Outperform from Market Perform at FBR Capital
TECK Teck Resources

09/22/17
DBAB
09/22/17
NO CHANGE
Target $26
DBAB
Buy
Teck Resources target raised to $26 after mine visit at Deutsche Bank
After visiting Red Dog in Alaska, the world's second largest zinc mine, Deutsche Bank analyst Chris Terry raised his price target on Teck Resources to $26 from $24. The analyst sees improved zinc production and a longer mine life from recent exploration success. He views Teck as undervalued and keeps a Buy rating on the shares.
09/18/17
09/18/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Teck Resources (TECK) initiated with a Sell at Axiom. 2. GenMark (GNMK) initiated with a Buy at BofA/Merrill. 3. Cirrus Logic (CRUS) initiated with an Underperform at BofA/Merrill. 4. Athenex (ATNX) initiated with an Outperform at Credit Suisse. 5. Brookfield Infrastructure (BIP) reinitiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/17
BOFA
10/04/17
NO CHANGE
Target $29
BOFA
Buy
Teck Resources price target raised to $29 from $27 at BofA/Merrill
BofA/Merrill analyst Timna Tanners raised Buy rated Teck Resources' price target to $29 from $27 saying Chinese aluminum and alumina capacity closures will continue to support high prices.
RIG Transocean

10/12/17
10/12/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Delta Air Lines (DAL) upgraded to Outperform from In-Line at Imperial Capital with analyst Michael Derchin saying the company is likely to grow unit revenues in fiscal year 2018 due to pricing power in its key domestic hubs and improving international results. 2. Transocean (RIG) upgraded to Buy from Neutral at Citi with analyst Scott Gruber saying if an upturn is forthcoming, Transocean should outperform given a "diminution" of concern toward its balance sheet and more new contract catalysts. 3. Canadian Pacific (CP) upgraded to Overweight from Neutral at JPMorgan with analyst Brian Ossenbeck saying he sees a shift to stronger volume growth as the company laps contract losses and records some new contract wins. 4. Infinity upgraded to Outperform from Market Perform at Wells Fargo with analyst Jim Birchenough saying the IPI-549 monotherapy data have a "reasonable likelihood" of proof-of-concept response rate, and with likely validation of tumor macrophage targeting in immunooncology and a unique mechanism of action, upside potential is not reflected in the current stock price. 5. Kroger (KR) upgraded to Equal Weight from Underweight at Stephens with analyst Ben Bienvenu saying he believes the pursuit of strategic alternatives for the convenience store business has potential to unlock value and that the risk/reward is more balanced following the stock's recent pullback. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/17
SBSH
10/12/17
DOWNGRADE
Target $12
SBSH
Sell
Diamond Offshore downgraded to Sell from Neutral at Citi
Citi analyst Scott Gruber downgraded Diamond Offshore (DO) to Sell and keeps a $12 price target for the shares. The analyst initiated a pair trade by also upgrading Transocean (RIG) this morning to Buy. Gruber, while still finding it premature to be bullish on offshore driller fundamentals, says that if an upturn is forthcoming, Transocean should outperform given a "diminution" of concern toward its balance sheet and more new contract catalysts. If the downturn persists, then Diamond Offshore is likely to underperform as its backlog is consumed, Gruber tells investors in a research note previewing Q3 earnings for the sector. He believes Diamond Offshore is "simply overvalued" and that Transocean is the "industry leader who's ready to lead."
10/12/17
SBSH
10/12/17
UPGRADE
Target $14
SBSH
Buy
Transocean upgraded to Buy from Neutral at Citi
Citi analyst Scott Gruber upgraded Transocean (RIG) to Buy and raised his price target for the shares to $14 from $8.80. The analyst initiated a pair trade by also downgrading Diamond Offshore (DO) to Sell. Gruber, while still finding it premature to be bullish on offshore driller fundamentals, says that if an upturn is forthcoming, Transocean should outperform given a "diminution" of concern toward its balance sheet and more new contract catalysts. If the downturn persists, then Diamond Offshore is likely to underperform as its backlog is consumed, Gruber tells investors in a research note previewing Q3 earnings for the sector. He believes Diamond Offshore is "simply overvalued" and that Transocean is the "industry leader who's ready to lead."
10/10/17
DBAB
10/10/17
INITIATION
Target $13
DBAB
Buy
Transocean initiated with a Buy at Deutsche Bank
Deutsche Bank analyst David Havens started Transocean with a Buy rating and $13 price target.
WFC Wells Fargo

09/26/17
DBAB
09/26/17
DOWNGRADE
Target $136
DBAB
Hold
PNC Financial downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Matt O'Connor downgraded PNC Financial (PNC) to Hold as he seeks to lessen exposure to traditional banks. The analyst sees net interest income growth slowing and credit costs inching up as the Fed raises short rates and the yield curve flattens. He believes a number of positives are priced into PNC shares. O'Connor upped his price target for the stock to $136 from $130. The analyst continues to prefer banks with a "turnaround angle," like Goldman Sachs (GS) and Wells Fargo (WFC), and remains positive on capital markets businesses like Morgan Stanley (MS). O'Connor this morning also downgraded JPMorgan (JPM) to Hold.
10/06/17
VERF
10/06/17
INITIATION
VERF
Sell
Wells Fargo initiated with a Sell at Vertical Group
Vertical Group analyst Richard Bove initiated earlier shares of Wells Fargo with a Sell rating and $49.67 price target.
09/28/17
NOMU
09/28/17
DOWNGRADE
NOMU
Neutral
U.S. Bancorp downgraded to Neutral from Buy at Nomura Instinet
Nomura Instinet analyst Bill Carcache downgraded U.S. Bancorp (USB) to Neutral saying he sees downside risk to net interest income and provision expectations. Consensus expects U.S. Bancorp's loan growth to accelerate to 6% by 2018, which is too optimistic given the bank's recent comments, the analyst contends. He lowered his price target for the shares to $55 from $57. Carcache remains bullish on Wells Fargo (WFC) and raised his price target for the shares to $65 from $64.
09/15/17
UBSW
09/15/17
NO CHANGE
Target $56
UBSW
Neutral
Wells Fargo revenue headwinds can persist, says UBS
UBS analyst Saul Martinez said proprietary analysis suggests Wells Fargo's difficult backdrop for client acquisition remains and the recent disclosures have kept the company in the spotlight for the wrong reasons. He believes earnings growth depends on efficiency improvement and more aggressive stock buybacks. Martinez maintained his Neutral rating and lowered his price target to $56 from $59 on Wells Fargo shares.
X U.S. Steel

09/22/17
COWN
09/22/17
DOWNGRADE
Target $20
COWN
Underperform
U.S. Steel downgraded to Underperform from Market Perform at Cowen
Cowen analyst Novid Rassouli downgraded U.S. Steel to Underperform and cut its price target to $20 from $24 based on expectations iron ore and U.S. HRC prices are heading lower. The analyst sees downside risk to U.S. Steel shares and earnings risk, especially in the U.S. Flat-rolled segment, given expectations for both iron ore and finished steel prices to move lower.
09/12/17
09/12/17
DOWNGRADE

Equal Weight
Nucor, Steel Dynamics downgraded on margin concerns at Morgan Stanley
As previously reported, Morgan Stanley analyst Piyush Sood downgraded Nucor (NUE) and Steel Dynamics (STLD), each to Equal Weight from Overweight, contending that the crosscurrents of higher U.S. steel and scrap pricing and weaker non-residential and auto demand are a drag on these "mini mills" and peer Commercial Metals (CMC). However, the net impact of the pricing and demand factors is beneficial to U.S. Steel (X), added Sood, who keeps an Overweight rating on that stock.
09/06/17
MACQ
09/06/17
INITIATION
MACQ
Outperform
U.S. Steel initiated with an Outperform at Macquarie
Macquarie analyst David Lipschitz initiated U.S. Steel with an Outperform and a $31 price target. The analyst said steel prices have recovered from the bottom due to low inventories and trade tariffs, giving steel companies breathing room on margins. Lipschitz expects near-term steel prices to decline modestly due to the delay of Section 232 investigation and an uncertain demand outlook, but believes hot roll coil price will normalize around $600/st beyond 2017 and will not test the lows of the previous cycle given supportive inventories and lead times. He said U.S. steel is better positioned in a steady demand growth environment and expects earnings to be resilient due to an improved cost structure and the asset revitalization program.
09/22/17
09/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Versartis (VSAR) was downgraded to Hold from Buy at SunTrust, to Underweight from Overweight at Barclays, to Neutral from Overweight at Piper Jaffray, and to Market Perform from Outperform at Cowen. 2. Tiffany (TIF) downgraded to Neutral from Buy at Goldman Sachs with analyst Lindsay Drucker Mann saying the company's high-end categories, including engagement, wedding and solitaire jewelry, decelerated in the last two quarters. 3. Airbus (EADSY) downgraded to Hold from Buy at Jefferies with analyst Sandy Morris saying the company's EBIT in fiscal 2018 and fiscal 2019 could track significantly below consensus expectations. 4. Alcoa (AA) downgraded to Hold from Buy at Berenberg with analyst Yuriy Vlasov saying Alcoa shares are up 43% over the past six months and recommends taking profits. 5. U.S. Steel (X) was downgraded to Underperform from Market Perform while ArcelorMittal (MT) was downgraded to Market Perform from Outperform at Cowen. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
C Citi

10/02/17
WELS
10/02/17
NO CHANGE
WELS
Outperform
Citi may have 'even more upside potential,' says Wells Fargo
Wells Fargo analyst Mike Mayo says Citigroup remains his top bank selection, but could have even more upside potential with restructuring. The analyst believes Citi can sell parts easier than realized, especially given only ''limited'' countries where consumer and institutional are highly integrated and an ability to divest consumer assets mostly by geography. Citi should at least remain open to more restructuring, he contends. He reiterates an Outperform rating on the shares.
09/11/17
SOCG
09/11/17
UPGRADE
SOCG
Hold
Citi upgraded to Hold from Sell at Societe Generale
10/09/17
FBCO
10/09/17
NO CHANGE
Target $83
FBCO
Outperform
Citi price target raised to $83 from $73 at Credit Suisse
Credit Suisse analyst Susan Roth Katzke raised her price target for Citi to $83 from $73 on valuation. The analyst reiterates an Outperform rating on the shares.
10/13/17
FBCO
10/13/17
NO CHANGE
Target $83
FBCO
Outperform
Citi decline on earnings due to soft credit card guidance, says Credit Suisse
Credit Suisse analyst Susan Katzke says yesterday's 3.4% slide in Citigroup stock price in spite of the earnings beat is likely due to its credit card guidance. Katzke says that even if Citi's North American card results fall 25% short of her forecast, it would result in a "manageable" 2% hit to EPS, maintaining her Outperform rating and $83 price target.
XLF Financial Select Sector

EFX Equifax

10/09/17
COWN
10/09/17
DOWNGRADE
Target $31
COWN
Underperform
Symantec downgraded to Underperform at Cowen
As reported previously, Cowen analyst Gregg Moskowitz downgraded Symantec (SYMC) to Underperform from Market Perform as he believes the recent spike in its price following the disclosure of the Equifax (EFX) breach is overdone. He also said its organic growth has been sluggish, its valuation is no longer cheap, and next-gen vendors are gaining traction. Moskowitz maintained his $31 price target on Symantec shares.
10/13/17
RHCO
10/13/17
NO CHANGE
RHCO
Equifax price target raised to $125 from $110 at SunTrust
SunTrust analyst Andrew W. Jeffrey raised his price target on Equifax as he believes that investors will begin to focus on what he sees as the company's "sustainable earnings power" and the likely acceleration of its growth in 2019. The analyst recommends buying the stock on any further weakness and keeps a Buy rating on the shares.
10/13/17
RHCO
10/13/17
NO CHANGE
RHCO
TransUnion price target raised to $56 from $48 at SunTrust
SunTrust analyst Andrew W. Jeffrey raised his price target on TransUnion (TRU), saying that he is "increasingly convinced" that the government will not implement legislation or regulations that will change the ratings agencies' businesses. The agencies' "central roles in the consumer credit ecosystem" make such a development unlikely, according to the analyst. Jeffrey views TransUnion as the best positioned name in the space, due to what he sees as its "next-gen software, differentiated solutions, proprietary data, strong management and first mover advantage in Consumer Indirect." The analyst believes that the latter business will be boosted by the Equifax (EFX) breach. He keeps a Buy rating on TransUnion.
10/06/17
WELS
10/06/17
NO CHANGE
Target $127
WELS
Outperform
Wells Fargo reiterates Outperform on Equifax after Congressional testimony
Wells Fargo analyst William Warmington reiterates an Outperform rating on Equifax with a $127 price target following three days of Congressional testimony by former CEO Rick Smith. The legislative proposals discussed were either high-probability/low-impact, like requiring companies meet minimum cybersecurity standards and have a reaction plan in event of a breach,or low-probability/high-impact, like allowing consumers to opt out of having Equifax track their data and mandatory per-account fines for data breaches, Warmington tells investors in a research note. The analyst expects investor focus to shift to Equifax's preliminary 2018 guidance on its upcoming Q3 earnings call. He thinks the company's long-term growth model remains intact and introduced above-consensus 2019 revenue and earnings per shares estimates of $3.77B and $6.80. Many investors expect 2018 to be a "transition year" with revenue and costs impacted by the breach, Warmington writes.
BAC Bank of America

08/09/17
WELS
08/09/17
INITIATION
WELS
Outperform
Bank of America resumed with an Outperform at Wells Fargo
Wells Fargo analyst Mike Mayo resumed coverage of Bank of America with an Outperform rating and $30 price target.
07/18/17
NOMU
07/18/17
NO CHANGE
Target $27
NOMU
Buy
Bank of America NII softness could weight on shares, says Nomura Instinet
Nomura Instinet analyst Steven Chubak said Bank of America reported a modest core beat but the NII miss and elevated bar for Q3 could result in modest share underperformance. The analyst remains encouraged by fee income resiliency, favorable credit trends, strong capital build, and compelling risk/reward, and reiterates his Buy rating and $27 price target.
07/11/17
BARD
07/11/17
NO CHANGE
BARD
Big bank set-up not great, would sell into extended rally, says Baird
Baird analyst David George does not see a great set-up for money-center banks heading into Q2 earnings. He said the trade looks crowded and he would be a seller into an extended rally. George said the risk/reward is less attractive following the sector's most recent rally as economic growth remains muted and the pace of NIM expansion may slow. George believes the biggest potential catalyst would be a gradual steepening of the yield curve and pick-up on loan growth.
06/09/17
RBCM
06/09/17
NO CHANGE
RBCM
House financial reform bill unlikely to advance in Senate, says RBC Capital
RBC Capital analyst Gerard Cassidy says that the financial regulation reform bill passed yesterday by the House would help the banking sector but probably won;t be passed by the Senate. Large publicly traded banks include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
T AT&T

09/27/17
JPMS
09/27/17
NO CHANGE
JPMS
Overweight
TiVo extension with AT&T shows strength of portfolio, says JPMorgan
JPMorgan analyst Sterling Auty believes TiVo's (TIVO) intellectual property license deal extension with AT&T (T) to 2025 demonstrates the strength of its patent portfolio and its usefulness to the pay-TV providers. The deal also shows the longevity of the value of TiVo's IP portfolio, Auty tells investors in a research note. He keeps an Overweight rating on the shares.
09/28/17
RAJA
09/28/17
NO CHANGE
RAJA
DOJ appointment catalyst for CenturyLink, Level 3 deal, says Raymond James
Makan Delrahim was finally confirmed by the Senate yesterday as head of the Department of Justice Antitrust Division, Raymond James analyst Frank Louthan tells investors in a research note. He believes not having an antitrust head is at least partially to blame for the delay in mergers and acquisitions in the Technology & Communications space this year, including outstanding transactions like CenturyLink (CTL)/Level 3 Communications (LVLT) and AT&T (T)/Time Warner (TWX), as well as potential deals like Sprint (S)/T-Mobile U.S. (TMUS). The appointment of Delrahim is a catalyst for the approval of CenturyLink's acquisition of Level 3, where the Department of Justice has been the bottleneck, Louthan writes.
09/20/17
OPCO
09/20/17
NO CHANGE
OPCO
Perform
Oppenheimer expects Sprint, T-Mobile merger to happen
Oppenheimer analyst Timothy Horan expect T-Mobile (TMUS) to merge with Sprint (S) in a stock-for-stock transaction at a $10 per share Sprint valuation. A T-Mobile/Sprint will be a better competitor to Verizon (VZ)/AT&T (T), the analyst says, adding that while the process is likely to have a few bumps and require time, he expects a merger to happen. Horan reiterates a Perform rating on Sprint's shares.
09/20/17
DBAB
09/20/17
NO CHANGE
DBAB
Sprint, T-Mobile merger unlikely to get regulatory approval, says Deutsche Bank
Deutsche Bank analyst Matthew Niknam continues to believe a potential merger between Sprint (S) and T-Mobile (TMUS) faces "significant hurdles" and is ultimately unlikely to get past regulatory concerns. Merits of the deal, however, are "unparalleled, and very tough to debate," Niknam tells investors in a research note following CNBC's report of progressing deal talks. He believes derivative stock reactions on the news, namely strength in AT&T (T) and Verizon (VZ) and weakness in the tower names, could be at risk of reversing. Among the towers, the analyst has Buy ratings on American Tower (AMT) and Crown Castle (CCI).

TODAY'S FREE FLY STORIES

WAC

Walter Investment

$0.51

-0.0056 (-1.09%)

10:24
10/21/17
10/21
10:24
10/21/17
10:24
Hot Stocks
Walter Investment reaches agreement on financial restructuring »

Walter Investment has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMST

TimkenSteel

$17.57

0.19 (1.09%)

10:18
10/21/17
10/21
10:18
10/21/17
10:18
Hot Stocks
Tentative agreement between TimkenSteel, United Steelworkers voted down »

TimkenSteel employees who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

AGEN

Agenus

$4.33

-0.14 (-3.13%)

, GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

10:15
10/21/17
10/21
10:15
10/21/17
10:15
Hot Stocks
FDA approves GlaxoSmithKline shingles vaccine with Agenus QS-21 Stimulon »

Agenus (AGEN) has…

AGEN

Agenus

$4.33

-0.14 (-3.13%)

GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 06

    Nov

MS

Morgan Stanley

$50.68

0.89 (1.79%)

10:06
10/21/17
10/21
10:06
10/21/17
10:06
Periodicals
Another 20% gain in Morgan Stanley stock likely, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

SSNLF

Samsung

10:02
10/21/17
10/21
10:02
10/21/17
10:02
Periodicals
Samsung has lots of upside driven by chips/screens, Barron's says »

Samsung stock is up 50%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 30

    Oct

DLAKY

Lufthansa

$30.28

0.2 (0.66%)

09:56
10/21/17
10/21
09:56
10/21/17
09:56
Periodicals
Lufthansa has more room to climb, Barron's says »

Amid competitor's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$59.90

0.12 (0.20%)

, DAL

Delta Air Lines

$53.27

1 (1.91%)

09:51
10/21/17
10/21
09:51
10/21/17
09:51
Periodicals
Market pounds United, sees American/Delta as possibly safe bets, Barron's says »

United Continental's…

UAL

United Continental

$59.90

0.12 (0.20%)

DAL

Delta Air Lines

$53.27

1 (1.91%)

AAL

American Airlines

$51.93

0.42 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 26

    Oct

  • 01

    Nov

CZR

Caesars

$12.20

0.15 (1.24%)

09:45
10/21/17
10/21
09:45
10/21/17
09:45
Periodicals
Caesars looks ready to grow again, Barron's says »

After a disastrous 2008…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 08

    Nov

DWDP

DowDuPont

$71.18

0.29 (0.41%)

09:40
10/21/17
10/21
09:40
10/21/17
09:40
Periodicals
DowDuPont shares likely to return as much as 30% over next year, Barron's says »

If DowDuPont can cut $3B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COH

Coach

$40.35

0.88 (2.23%)

09:29
10/21/17
10/21
09:29
10/21/17
09:29
Periodicals
Coach shares look undervalued, could rise nearly 30%, Barron's says »

Coach, which has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$96.50

1.8 (1.90%)

, MOH

Molina Healthcare

$64.40

0.76 (1.19%)

09:24
10/21/17
10/21
09:24
10/21/17
09:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

CNC

Centene

$96.50

1.8 (1.90%)

MOH

Molina Healthcare

$64.40

0.76 (1.19%)

CI

Cigna

$191.42

3.2 (1.70%)

ANTM

Anthem

$194.69

1.49 (0.77%)

AET

Aetna

$160.84

3.2 (2.03%)

HNT

Health Net

HUM

Humana

$245.81

3.12 (1.29%)

UNH

UnitedHealth

$207.49

4.24 (2.09%)

WCG

WellCare

$180.52

3.28 (1.85%)

CYH

Community Health

$6.44

0.24 (3.87%)

HCA

HCA Healthcare

$81.05

1.26 (1.58%)

LPNT

LifePoint

$58.35

0.5 (0.86%)

THC

Tenet

$14.66

1.31 (9.81%)

UHS

Universal Health

$112.85

2.31 (2.09%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

MSFT

Microsoft

$78.81

0.9 (1.16%)

FB

Facebook

$174.98

0.42 (0.24%)

INTC

Intel

$40.43

0.34 (0.85%)

IBM

IBM

$162.07

1.17 (0.73%)

MAR

Marriott

$115.02

-0.18 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 02

    Nov

  • 02

    Nov

  • 03

    Nov

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 08

    Nov

  • 15

    Nov

  • 15

    Nov

  • 29

    Nov

  • 30

    Nov

  • 18

    Mar

ETFC

E-Trade

$43.20

-0.49 (-1.12%)

08:55
10/21/17
10/21
08:55
10/21/17
08:55
Conference/Events
E-Trade to hold an education day »

Chicago Education Day is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

08:45
10/21/17
10/21
08:45
10/21/17
08:45
General news
Breaking General news story  »

New York Federal Reserve…

FB

Facebook

$174.98

0.42 (0.24%)

, AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

08:25
10/21/17
10/21
08:25
10/21/17
08:25
Periodicals
Regulators inquiries fuel speculation about big tech breakup, Barron's says »

Facebook (FB), Amazon…

FB

Facebook

$174.98

0.42 (0.24%)

AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 26

    Oct

  • 26

    Oct

  • 01

    Nov

  • 08

    Nov

  • 15

    Nov

  • 29

    Nov

  • 18

    Mar

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

07:58
10/21/17
10/21
07:58
10/21/17
07:58
Hot Stocks
DBV believes FDA suggested continue moving forward with Viaskin »

DBV Technologies (DBVT)…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

04:55
10/21/17
10/21
04:55
10/21/17
04:55
General news
Breaking General news story  »

New York Federal Reserve…

ETFC

E-Trade

$43.20

-0.49 (-1.12%)

04:55
10/21/17
10/21
04:55
10/21/17
04:55
Conference/Events
E-Trade to hold an education day »

Chicago Education Day is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.